<DOC>
	<DOCNO>NCT02214940</DOCNO>
	<brief_summary>First evaluation safety , tolerability , pharmacokinetics , pharmacodynamic effect BI 11634 coagulation parameter multiple-dose administration ( primary endpoint statistical sense define )</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Multiple , Rising Oral Doses BI 11634 Oral Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy Caucasian male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test Age ≥18 ≤50 year Haemoglobin within normal range Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Relevant surgery gastrointestinal tract History bleed disorder acute chronic blood coagulation defect , subject person family far known History gastric ulcera cholecystectomy Occult blood feces Relevant diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout Relevant chronic acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Use acetylsalicylic acid nonsteroidal antiinflammatory drug ( NSAID ) within 2 week study start end study Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day judge investigator Alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Vulnerable subject ( e.g . person keep detention ) The subject able understand comply protocol requirement , instruction protocolstated restriction Subjects history within past six week closedhead torso trauma deceleration injury automobile accident fall significant height Inability comply dietary regimen study centre Inability understand protocol requirement , instruction studyrelated restriction ; nature , scope possible consequence study Subjects ( include vasectomy ) agree use two method contraception , include barrier contraception ( latex condom spermicide plus intrauterine device ) engage sexual activity woman child bear potential study 60 day completion study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>